Results: 7
Correction to: Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
The Opportunity of Point-of-Care Diagnostics in General Practice: Modelling the Effects on Antimicrobial Resistance.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 823, doi. 10.1007/s40273-022-01165-3
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in Australia.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 807, doi. 10.1007/s40273-022-01156-4
- By:
- Publication type:
- Article
Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 791, doi. 10.1007/s40273-022-01152-8
- By:
- Publication type:
- Article
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 743, doi. 10.1007/s40273-022-01148-4
- By:
- Publication type:
- Article
Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 777, doi. 10.1007/s40273-022-01145-7
- By:
- Publication type:
- Article
The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 8, p. 751, doi. 10.1007/s40273-022-01140-y
- By:
- Publication type:
- Article